Sawabata Noriyoshi, Fujii Yoshitaka, Asamura Hisao, Nomori Hiroaki, Nakanishi Yoichi, Eguchi Kenji, Mori Masaki, Okumura Meinoshin, Miyaoka Etsuo, Yokoi Kohei
Department of General Thoracic Surgery, Osaka University Graduate School of Medicine.
Nihon Kokyuki Gakkai Zasshi. 2011 Apr;49(4):327-42.
The Japan Lung Cancer Society, Japanese Association for Chest Surgery, and Japanese Respiratory Society jointly established the Japanese Joint Committee for Lung Cancer Registration. In 2010, analyses of 11,663 cases of lung cancer that underwent surgical resection in 2004 were performed, then the findings were registered and collected for analysis by the committee. The survival rate for all cases was 69.6%, while the 5-year survival rate in males (n = 7.369) was 63.0% and 80.9% in females (n = 4,294). The 5-year survival rates by c-stage (UICC Ver. 6 and Ver. 7) were as follow: IA (n = 6,295, 6,295), 82.0% and 82.0%; IB (n = 2,788, 2,339), 63.4% and 66.1%, IIA (n = 203, 819), 55.4% and 54.5%; IIB (n = 899, 648), 48.6% and 46.4%: IIIA (n = 940, 1,216), 43.3% and 42.8%; IIIB (n = 407, 90), 41.6% and 40.3% and IV (n = 131, 256), 29.1% and 31.4%, respectively. The 5-year survival rates by p-stage (UICC Ver. 6 and Ver. 7) were as follow: IA (n = 5,611, 4,978), 85.9% and 86.8%; IB (n = 2,398, 2,552), 69.3% and 73.9%; IIA (n = 336, 941), 60.9% and 61.6%; IIB (n = 977, 848), 51.1% and 49.8%; IIIA (n = 1354, 1804), 41.0% and 40.9%; IIIB (n = 799, 106), 36.7% and 27.8%, and IV (n = 188, 434), 27.8% and 27.9%, respectively. The 5-year survival rates by histological type were as follow: adenocarcinoma, 74.9% squamous cell carcinoma, 59.1%; large cell carcinoma, 53.3% small cell carcinoma, 52.6%; and adenosquamous cell carcinoma, 50.8%. Operative death occurred in 48 cases (0.4%) and hospital death in 46 (0.4%).
日本肺癌协会、日本胸部外科学会和日本呼吸学会联合成立了日本肺癌登记联合委员会。2010年，对2004年接受手术切除的11663例肺癌病例进行了分析，然后该委员会对研究结果进行了登记和收集以进行分析。所有病例的生存率为69.6%，男性（n = 7369）的5年生存率为63.0%，女性（n = 4294）为80.9%。按c分期（国际抗癌联盟第6版和第7版）的5年生存率如下：IA期（n = 6295，6295），82.0%和82.0%；IB期（n = 2788，2339），63.4%和66.1%；IIA期（n = 203，819），55.4%和54.5%；IIB期（n = 899，648），48.6%和46.4%；IIIA期（n = 940，1216），43.3%和42.8%；IIIB期（n = 407，90），41.6%和40.3%；IV期（n = 131，256），分别为29.1%和31.4%。按p分期（国际抗癌联盟第6版和第7版）的5年生存率如下：IA期（n = 5611，4978），85.9%和86.8%；IB期（n = 2398，2552），69.3%和73.9%；IIA期（n = 336，941），60.9%和61.6%；IIB期（n = 977，848），51.1%和49.8%；IIIA期（n = 1354，1804），41.0%和40.9%；IIIB期（n = 799，106），36.7%和27.8%；IV期（n = 188，434），分别为27.8%和27.9%。按组织学类型的5年生存率如下：腺癌，74.9%；鳞状细胞癌，59.1%；大细胞癌，53.3%；小细胞癌，52.6%；腺鳞癌，50.8%。手术死亡48例（0.4%），医院死亡46例（0.4%）。
